Researchers have engineered T cells directly inside the living body, successfully eliminating cancer in mice. The breakthrough aims to bypass the weeks of delay and costs associated with standard CAR-T therapies.
Overcoming the High Costs and Manufacturing Delays of Standard CAR-T
While conventional chimeric antigen receptor T-cell treatments have revolutionized how certain blood cancers are managed, the logistical process of delivering them to patients remains sluggish, costly, and complex. To perform the standard procedure, clinicians must harvest a patient’s immune cells, transport them to a specialized laboratory, and perform genetic modifications so the cells can identify malignancy. Once a sufficient volume of CAR T cells has been cultivated, they are transported back to the clinical site and injected into the patient. In recent years, scientists have begun using a similar strategy to create CAR natural killer (NK) cells.
Their production depends on specialized facilities. Patients generally must also undergo intensive preparatory chemotherapy to clear space in the bone marrow, an exhausting regimen for older or medically frail individuals.
I think this is just the beginning of a big wave of new therapies that will be truly transformational and save a lot of lives.
Justin Eyquem, UCSF
Targeting Precise Genetic Insertion Inside Living Mouse Models
Justin Eyquem, an associate professor of medicine at UCSF and the senior author of the new paper, and collaborators developed a system based on two different particles. Its surface is covered with antibodies that recognize CD3, a protein found exclusively on T cell surfaces, which helps direct the gene-editing machinery specifically toward T cells. The second particle delivers DNA containing the instructions for producing the cancer-fighting CAR, while also carrying information that directs the new DNA to a precise location within the T cell genome.
The researchers also designed the particles to avoid being immediately destroyed by the immune system. Within certain organs, the proportion of newly engineered CAR-T cells reached up to 40% of the total immune cell population; furthermore, the therapy successfully eradicated cancer from the spleen and bone marrow while showing efficacy against multiple myeloma.
Expanding Beyond Blood Cancers Into Solid Tumors and Unexpected Advantages
Furthermore, MIT engineers created a method to utilize lipid nanoparticles to transport messenger RNA straight into NK cells in vivo, thereby programming these natural killer cells to attack cancerous or autoreactive T cells linked to conditions like autoimmune hepatitis and lymphoma, all without needing to extract the cells from the patient. This research was led by MIT graduate students Haseeb Mughal and Julia Monkovic alongside MIT postdoc Yuang Chen, with Robert Langer, the David H. Koch Institute Professor at MIT, also serving as an author.
Justin Eyquem emphasized the broader potential if the technology successfully transitions to human patients, noting it is not yet ready for patients.
If we can translate this to humans, we could dramatically reduce costs, eliminate waiting times, and potentially allow community hospitals — not just major cancer centers — to offer these life-saving therapies. That would truly democratize access to CAR-T cell therapy.
Justin Eyquem, UCSF
Practical next step: Patients and families interested in emerging immunotherapies should consult qualified medical professionals and oncologists regarding current clinical trials and treatment options, as this research remains preclinical and is not yet ready for patients.